<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Customised Solutions | Pharma Advancement</title>
	<atom:link href="https://www.pharmaadvancement.com/tag/customised-solutions/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.pharmaadvancement.com</link>
	<description>Latest Pharmaceutical News</description>
	<lastBuildDate>Tue, 27 Jan 2026 10:34:20 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.11</generator>

<image>
	<url>https://www.pharmaadvancement.com/wp-content/uploads/2025/12/cropped-Pharmaa-Dvancement-Fevicon-32x32.jpg</url>
	<title>Customised Solutions | Pharma Advancement</title>
	<link>https://www.pharmaadvancement.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Cold Chain Innovation for Temperature Sensitive Medicines</title>
		<link>https://www.pharmaadvancement.com/packaging-logistic/cold-chain-innovation-for-temperature-sensitive-medicines/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Tue, 27 Jan 2026 10:34:20 +0000</pubDate>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Supply Chain & Logistics]]></category>
		<category><![CDATA[Trends]]></category>
		<category><![CDATA[Customised Solutions]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/cold-chain-innovation-for-temperature-sensitive-medicines/</guid>

					<description><![CDATA[<p>Advances in thermal packaging, real-time monitoring, and sustainable cooling technologies are revolutionizing the way sensitive biologics and vaccines are transported, ensuring their efficacy remains uncompromised from the production line to the patient.</p>
The post <a href="https://www.pharmaadvancement.com/packaging-logistic/cold-chain-innovation-for-temperature-sensitive-medicines/">Cold Chain Innovation for Temperature Sensitive Medicines</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p>The pharmaceutical landscape is shifting toward increasingly complex therapies, many of which are derived from living organisms. These biologics, vaccines, and cell therapies are inherently unstable and highly sensitive to environmental conditions, particularly temperature. As these products become a larger share of the global drug market, the demand for sophisticated pharma cold chain innovation has reached a fever pitch. Traditional refrigeration methods are no longer sufficient to handle the rigorous requirements of a modern medical portfolio. Instead, a new era of temperature controlled logistics is emerging, characterized by advanced material science, ubiquitous connectivity, and a relentless focus on preserving the therapeutic integrity of every shipment. This evolution is vital for ensuring that the promise of modern medicine is fulfilled regardless of where a patient is located in the world.</p>
<h3><strong>Advanced Material Science in Thermal Packaging</strong></h3>
<p>At the heart of cold chain advancement lies the development of high-performance packaging solutions designed to withstand the unpredictability of global transit. For years, the industry relied heavily on bulky expanded polystyrene (EPS) containers and simple gel packs, which provided limited protection and often resulted in significant waste. Today, the focus has shifted toward vacuum-insulated panels (VIPs) and phase change materials (PCMs). These materials offer superior thermal resistance in a much smaller footprint, allowing for more efficient use of cargo space. PCMs, in particular, are a game-changer; they can be engineered to maintain specific temperature points such as 2°C to 8°C or even ultra-frozen states for extended periods without the need for an active power source.</p>
<p>The adoption of VIP technology provides up to ten times the insulation value of traditional materials, meaning that even a thin layer can protect a shipment from extreme ambient heat during a long international flight or a delay on a hot airport tarmac. Furthermore, these advanced materials are often designed for reuse, aligning with the industry&#8217;s growing focus on sustainability. By moving away from disposable single-use shippers, companies can reduce their environmental footprint while simultaneously improving the reliability of their biologics distribution. The challenge remains in managing the reverse logistics of these high-value containers, but the superior protection they offer makes them an essential component of the modern pharmaceutical supply chain.</p>
<h4><strong>The Evolution of Active Cooling Systems</strong></h4>
<p>While passive systems are ideal for many applications, the transport of high-volume or extremely sensitive shipments often requires active temperature controlled logistics. Modern active containers have evolved from simple &#8220;refrigerators on wheels&#8221; into intelligent, self-contained climate units. These systems utilize advanced compressor technology and rechargeable battery packs to provide consistent cooling for days on end. The latest innovations include hybrid systems that can switch between active power and passive thermal reservoirs, providing multiple layers of redundancy. This is particularly vital for vaccine logistics, where the scale of distribution during public health emergencies requires systems that can handle both the bulk movement of doses and the individual &#8220;last-mile&#8221; delivery to clinics.</p>
<p>These active systems are also becoming more &#8220;connected.&#8221; Many now feature built-in GPS and cellular transmitters that provide real-time updates on internal conditions and location. This allows logistics teams to monitor the health of the cooling system remotely and take action if a battery is low or if a door has been left open. Some advanced units even allow for remote temperature adjustment, giving operators the ability to fine-tune the environment from thousands of miles away. This level of control is essential for therapies that have extremely narrow &#8220;stability budgets,&#8221; where even a few degrees of deviation can render a batch unusable. The move toward active systems is essentially turning the shipping container into a mobile laboratory, maintaining the same standards of quality found in a manufacturing facility.</p>
<h4><strong>Smart Monitoring and Real-Time Visibility</strong></h4>
<p>Innovation in the cold chain is as much about information as it is about insulation. The integration of IoT-enabled sensors has revolutionized how companies manage their pharma cold chain. These devices do more than just record the temperature at the end of a journey; they provide real-time updates on humidity, light exposure, and physical shock. If a container is left on a sun-drenched tarmac or if a cooling unit fails, the system triggers an immediate alert to the logistics team. This allows for proactive intervention such as moving the shipment to a cold room or adjusting the cooling settings remotely before the product is compromised. This level of visibility is the new standard for cold chain compliance, providing a digital &#8220;birth-to-death&#8221; certificate for every medicine.</p>
<p>Furthermore, the data generated by these sensors is being used to build predictive models that can identify &#8220;risk zones&#8221; in the global distribution network. By analyzing thousands of previous shipments, companies can identify which routes or handling facilities are most prone to temperature excursions. This intelligence allows logistics planners to select more reliable paths or to specify extra protection for particularly challenging segments of a journey. Over time, this data-driven approach shifts the focus from simple monitoring to systemic prevention. Instead of reacting to problems, the industry is building a &#8220;smart&#8221; network that learns from every shipment, continuously improving its ability to protect the most sensitive medicines.</p>
<h3><strong>Navigating the Challenges of Biologics Distribution</strong></h3>
<p>Biologics distribution presents a unique set of challenges that go beyond simple temperature maintenance. Many of these products are not only sensitive to heat but also to freezing and excessive vibration. Furthermore, the high cost of individual doses means that any loss has a significant financial and clinical impact. To address this, logistics providers are developing specialized &#8220;white-glove&#8221; services that prioritize these sensitive assets. This includes dedicated transport lanes, specialized handling protocols at airports, and the use of blockchain technology to ensure an immutable record of custody. By combining physical protection with digital transparency, the industry is creating a &#8220;seamless&#8221; cold chain that minimizes the variables that can lead to product degradation.</p>
<p>The complexity is further compounded by the rise of &#8220;direct-to-patient&#8221; delivery models. As more clinical trials and chronic disease management move to the home, the cold chain must extend into the residential setting. This requires packaging that is not only effective but also easy for a patient or a caregiver to handle. Innovations in this area include smart refrigerators for the home that can alert the pharmacy if a product has been stored incorrectly. Extending the cold chain into the home is the final frontier of pharma cold chain innovation, requiring a delicate balance of high-tech protection and user-friendly design. Successfully bridging this gap is essential for the future of decentralized healthcare and the growing demand for convenient, home-based treatments.</p>
<h3><strong>Regulatory Standards and Cold Chain Compliance</strong></h3>
<p>Maintaining high standards in the cold chain is not just a best practice; it is a regulatory requirement. Health authorities worldwide, including the FDA and EMA, have intensified their focus on Good Distribution Practices (GDP). Cold chain compliance now requires rigorous validation of all packaging and equipment, as well as comprehensive training for all personnel involved in the process. Digitalization plays a key role here by automating the documentation process. Automated reports can now be generated for every shipment, proving that the required temperature range was maintained throughout its journey. This transparency not only satisfies regulators but also builds trust with healthcare providers and patients who rely on these medicines for their well-being.</p>
<p>As regulations continue to evolve, the industry must stay ahead of the curve by adopting more sophisticated quality management systems. This includes the use of &#8220;electronic quality management systems&#8221; (eQMS) that can integrate cold chain data directly into the broader quality record. This integration allows for a more holistic view of product quality, linking logistical performance to manufacturing standards and clinical outcomes. The goal is to move toward a state of &#8220;continuous compliance,&#8221; where every aspect of the distribution network is being monitored and audited in real-time. By embracing these standards, the pharmaceutical industry is demonstrating its unwavering commitment to the safety and efficacy of the products it delivers to the global population.</p>
<p>The future of pharmaceutical distribution will be defined by its ability to handle the coldest and most sensitive of products with absolute precision. As gene therapies and personalized medicines become more common, the infrastructure supporting them must continue to advance. The ongoing investment in pharma cold chain innovation is a testament to the industry&#8217;s commitment to patient safety. By harnessing the power of new materials, intelligent sensors, and global connectivity, we are building a distribution network that is capable of delivering the miracles of modern medicine to any corner of the globe, safely and effectively. The cold chain is no longer just a logistical hurdle; it is a vital extension of the manufacturing process itself, ensuring that the promise of a therapy is fully realized when it reaches the patient.</p>The post <a href="https://www.pharmaadvancement.com/packaging-logistic/cold-chain-innovation-for-temperature-sensitive-medicines/">Cold Chain Innovation for Temperature Sensitive Medicines</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FDA Unveils Plausible Mechanism Pathway for Custom Therapies</title>
		<link>https://www.pharmaadvancement.com/drug-development/fda-unveils-plausible-mechanism-pathway-for-custom-therapies/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Thu, 20 Nov 2025 11:12:21 +0000</pubDate>
				<category><![CDATA[Americas]]></category>
		<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[FDA Approvals]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Customised Solutions]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/fda-unveils-plausible-mechanism-pathway-for-custom-therapies/</guid>

					<description><![CDATA[<p>The US Food and Drug Administration (FDA) has unveiled a new regulatory framework designed to accelerate the approval of personalised therapies by easing traditional requirements. The initiative, termed the “plausible mechanism pathway,” was inspired by the landmark case of Baby KJ, whose life-saving gene-editing treatment became the model for this approach. Baby KJ, a newborn [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/drug-development/fda-unveils-plausible-mechanism-pathway-for-custom-therapies/">FDA Unveils Plausible Mechanism Pathway for Custom Therapies</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p>The US Food and Drug Administration (FDA) has unveiled a new regulatory framework designed to accelerate the approval of personalised therapies by easing traditional requirements. The initiative, termed the “plausible mechanism pathway,” was inspired by the landmark case of Baby KJ, whose life-saving gene-editing treatment became the model for this approach.</p>
<p>Baby KJ, a newborn diagnosed with carbamoyl-phosphate synthetase 1 (CPS1) deficiency, a rare and severe metabolic disorder, was treated under a single-patient, expanded-access investigational new drug (IND) application that the FDA processed within a week. The patient’s medical team developed a customised CRISPR-based therapy to repair the underlying gene defect. In May 2025, KJ became the first individual worldwide to receive a bespoke CRISPR treatment, marking a milestone that would later shape the new regulatory pathway.</p>
<p>Under the new framework, the FDA will consider therapies targeting well-defined molecular or cellular abnormalities rather than broadly characterised diseases. To qualify, the treatment must act on the biological source of the disorder and address a condition with a clearly documented natural history. Evidence of successful gene or molecular targeting through animal or non-animal models, or biopsy where relevant, will be required. Moreover, the product must show measurable improvement in patient outcomes, with the agency applying a lower threshold for diseases that cause progressive decline. Notably, the plausible mechanism pathway eliminates the need for traditional clinical trial data, relying instead on expanded-access programmes to gather real-world safety and efficacy information.</p>
<p>The FDA will grant marketing authorisation once developers demonstrate consistent success across several patients, continuing to monitor long-term results through real-world evidence (RWE). While the scheme prioritises rare disorders, it could extend to more common conditions lacking proven treatments.</p>
<p>The move aligns with the Trump administration’s efforts to expand access to personalised therapies and reduce long-term treatment costs.</p>The post <a href="https://www.pharmaadvancement.com/drug-development/fda-unveils-plausible-mechanism-pathway-for-custom-therapies/">FDA Unveils Plausible Mechanism Pathway for Custom Therapies</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Building the Right Team and Resource Model to Support Quality System and Validation Activities</title>
		<link>https://www.pharmaadvancement.com/market-moves/building-the-right-team-and-resource-model-to-support-quality-system-and-validation-activities/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Thu, 13 Nov 2025 06:11:17 +0000</pubDate>
				<category><![CDATA[Drug Development]]></category>
		<category><![CDATA[Insights]]></category>
		<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[Customised Solutions]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/building-the-right-team-and-resource-model-to-support-quality-system-and-validation-activities/</guid>

					<description><![CDATA[<p>Since life science quality and validation projects can vary widely in scope and complexity, each specific project needs to be evaluated in order to determine the resources and technical disciplines appropriate for anticipated tasks. Highly trained specialists in the areas of regulatory, quality, IT, engineering and others, are relied upon to plan, implement, and monitor [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/market-moves/building-the-right-team-and-resource-model-to-support-quality-system-and-validation-activities/">Building the Right Team and Resource Model to Support Quality System and Validation Activities</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p>Since life science quality and validation projects can vary widely in scope and complexity, each specific project needs to be evaluated in order to determine the resources and technical disciplines appropriate for anticipated tasks.</p>
<p>Highly trained specialists in the areas of regulatory, quality, IT, engineering and others, are relied upon to plan, implement, and monitor qualification and/or validation activities in highly regulated industries, such as pharmaceutical and medical device manufacturing. These projects and programs may include activities like writing and executing CQV and CSV protocols; ensuring documentation, SOPs, laboratory, manufacturing and packaging operations are robust; creating and running test scripts; analyzing existing processes for improvement opportunities; and auditing the documentation trail for compliance. The processes behind these activities must demonstrate that they lead to a consistent, high-quality product, and are central to producing safe and effective products in a fully compliant state. This article describes critical steps an organization can follow to ensure Commissioning, Qualification and Validation (CQV) and Computer Software Assurance (CSA) program success every time. Forming the right team and staffing model from the get-go with the right skillset is critical before the project even initiates.</p>
<h3><strong>Creating a Multi-Disciplinary Team of Specialists</strong></h3>
<p>The practice of using multi-disciplinary teams to support the qualification and validation of new or modified systems, facilities, and processes has become an expectation of the FDA as well as many other regulatory agencies in ICH markets. In addition to drafting and executing protocols, effective quality and validation teams also ensure that any changes made to systems, equipment or processes do not result in compliance gaps.</p>
<p>Finding, evaluating, and securing the right talent for a specific validation project can be a challenge. However, the following types of expertise should be evaluated to help you get the right team established from the project start. Oftentimes, organizations look to specialized consulting and staffing companies with the required level of expertise to fulfill their needs. Sometimes they even outsource the entire validation and quality effort to focus on other high priority projects. A winning formula would be for organizations to ensure they are properly staffed at the right time and can flex to meet changing resource requirements.</p>
<h3><strong>SKILLSETS TO LOOK FOR</strong></h3>
<p>Operations Expertise (Filling, Packaging, Assembly, CSV, CQV, Controls, etc.)</p>
<p>Determine if, and to what degree your project will require, highly specialized support. Is direct equipment or process experience critical or valuable? For example, a pharmaceutical manufacturer may need specific operations support in formulation, equipment/component preparation, final filling, product inspection, and packaging. Defining these skillsets for your specific project is helpful in both assessing candidates for specific capabilities, and once your team is built, ensuring you have the expertise to support those areas.</p>
<p>✓ Which specific operations will you need to support?</p>
<p>✓ What skills, capabilities, or experience are essential to ensuring those unit operations can be adequately supported?</p>
<p>What skills, capabilities, or experience are essential to ensuring those unit operations can be adequately supported?</p>
<p>Carefully evaluate and consider all requirements related to the product and equipment to ensure your specialists have the knowledge and experience to perform the activities they are supporting and responsible for.</p>
<p>✓ What are the specific requirements for the product, equipment, or project in question?</p>
<p>✓ What specific qualities, capabilities, or experience must a specialist have to satisfy these requirements? For example, is previous sterile room experience critical?</p>
<p>Environmental Requirements (Aseptic, Non-Aseptic, BSL, Cyto/Gen Toxic, etc.)</p>
<p>Similar to product requirements, does the project or program require the validation and quality team to operate within a restricted environment? Do they need to be aseptic area qualified with years of experience operating in that environment? If a specialist lists themselves as having performed EMPQ support, for instance, probe further to understand what that means in terms of tangible project work. More importantly, determine which questions you need to ask in order to understand how they apply the experience within the context of your project. This is one area where routine validation projects with more general requirements differ from specialized process work where specific experience may play a larger role.</p>
<p>✓ What specific environmental requirements for the product or project are in question?</p>
<p>✓ What specific qualities, capabilities, or experience must a specialist have to satisfy these environmental requirements?</p>
<p>Vision Inspection Systems (Defect Sets, Defect Logs, Personnel Qualification, etc.)</p>
<p>Some Validation and Quality projects may require specialists who have experience with vision inspection systems. This type of expertise can be difficult to find if it necessitates knowing the requirements for validating camera systems.</p>
<p>✓ What specific inspection equipment are you looking to validate?</p>
<p>✓ What are the internal requirements for the system?</p>
<p>✓ Do you have defect sets needed to validate such equipment?</p>
<p>Strong Documentation Skills GMP (Compliant Documentation, Protocol Generation, Digital expertise, etc.)</p>
<p>If the project involves drafting and executing documents, specialists must be able to produce documentation that complies with both internal SOPs and external regulations. Having backgrounds and personal experience navigating the rigors of creating compliant documents that are genuinely clear and easy to follow are critical.</p>
<p>✓ Which specific operations will you need to support?</p>
<p>✓ What is the expectation for specialists in terms of protocol drafting and execution?</p>
<p>✓ What is the training process required prior to gaining access to the internal documentation control system?</p>
<p>✓ Will the specialists be required to initiate and drive change controls?</p>
<h3><strong>Selecting the Right Resource Model: An Opportunity for Managed Services</strong></h3>
<p>After determining the skillsets you need for your programs, it’s important to consider how you will staff your team. There are different staffing models that can be considered – from hiring in-house to staff augmentation to a full managed services engagement. The advantages and disadvantages of each model are depicted below in Figure 1.</p>
<p>Many organizations look to outsourcing because it affords a flexible, scalable and oftentimes, less expensive model for hiring the expertise they need. While staff augmentation had traditionally been the model of acquiring staff, it does have its own drawbacks. Enter managed services: A flexible solution that offers a unique combination of a deeper, ongoing partnership and institutional knowledge, while optimizing processes and implementing continuous improvements.</p>
<p>A managed services model allows your internal employees to focus on the company’s core business of bringing medical products to market, while having the confidence that your regulatory and compliance requirements are met.</p>
<p>Not all Managed Services Providers (MSPs) are created equal. How do you know you’re getting the managed services care you need? The overall goal of an MSP is to fit into your organization like an internal team member. The provider should be on board with your vision, goals and priorities, while providing the expertise, resources, technology, infrastructure and continuous improvements you need for essential non-core functions.</p>
<p>The following functional areas are best suited by a managed services solution that can take over the entire function and implement best practices. It also provides full visibility into how the function fits into the bigger drug development, go-to-market and commercial production strategies.</p>
<h3><strong>COMPUTER SYSTEMS VALIDATION (CSV)</strong></h3>
<p>While a highly specialized and essential area, CSV is a paramount for regulatory compliance, and these activities from custom should not be treated lightly. It is a capability that all life sciences companies must perform consistently and accurately. CSV is a multi-faceted function covering a wide range of validated computer systems across the entire business. At any point it can span the research, clinical testing, manufacturing and distribution process. It is especially complicated with the influx of cloud-based computer systems along with the traditional on-premise systems. This added complexity is why most organizations would benefit from wrapping their quality and compliance functions into a managed services engagement, from vendor auditing through computer system validation testing.</p>
<p><strong>CLIENT VALUE</strong></p>
<p>✓ Ensure consistent and compliant CSV with expert insight and services, from custom implementations to agile project and audit management</p>
<p>✓ Transform your review and approval process with the strategic implementation of industry-leading tools, plus expert training and ongoing maintenance</p>
<p>✓ Implement best-in-class processes that allow you to have the confidence in the accuracy, reliability and consistency all while ensuring data integrity is maintained</p>
<h3><strong>COMMISSIONING, QUALIFICATION AND VALIDATION (CQV) </strong></h3>
<p>Ensuring that manufacturing facilities, equipment and utilities are commissioned and qualified, and that processes are validated, is critical for success in the life sciences industry. In addition to optimizing the cost of ownership and maintaining your manufacturing systems in a validated state, a managed service approach provides continuous improvements to ensure assets are optimized and running as effectively and efficiently as possible. It also actively supports operations so emphasis can be placed on customers and business needs.</p>
<p><strong>CLIENT VALUE</strong></p>
<p>✓ Ensure equipment, facilities and processes are maintained in a validated state utilizing the latest technologies and proven delivery strategies from up-front project planning through process validation</p>
<p>✓ Employ diverse and flexible technical expertise and cost-effective staffing strategies and software tools (such as paperless validation) to deliver projects on schedule and on budget to accelerate speed to market</p>
<p>✓ Implement continuous improvements that result in improved system reliability, increased efficiency and cost reductions</p>
<h3><strong>INFORMATION MANAGEMENT AND ANALYTICS (IMA)</strong></h3>
<p>All organizations must deal with a variety of data from applications, third party vendors and government agencies. Managing this information in a highly regulated industry can be difficult and time consuming, as well as risky. Regulatory bodies require data integrity throughout the produce lifecycle to ensure that products are safe. Many organizations do not have the time, resources or skills to do this effectively. Managing data and analytics involves organizing, labeling and structuring information from disparate sources while following guidelines such as ALCOA+, GDPR and the Sunshine Act. While this area can be complex, it is very well defined and repeatable under a solid data architecture. With hundreds, if not thousands, of integration and consolidation programs, this can be overwhelming for IT departments. Most of the activities such as meta data and data integration can be performed via a managed services provider.</p>
<p><strong>CLIENT VALUE</strong></p>
<p>✓ Offload mundane, repeatable and known activities such as data wrangling, test and training model preparation, model tuning and optimization so your data scientist can do more and experience better job satisfaction</p>
<p>✓ Draw actionable insights from raw data via advanced analytics and best practice steps</p>
<p>✓ Employ critical thinking experts who ask the right questions to meet key success metrics in the analytics-related field</p>
<p>It is entirely possible to outsource specific functions that make the most sense to one or multiple MSPs depending on your relationship and preferences. This does not relieve the company from its compliance obligations, so the final approval is always up to an internal team member. These areas merely scratch the surface of where and how an MSP can support your organization so you can focus on your core business – bringing safe and compliant products to market.</p>
<h3><strong>Conclusion</strong></h3>
<p>No matter where you are in the product development or commercialization lifecycle, building a team from the start that has the right expertise, is an imperative for all validation and quality projects. A thoughtful evaluation of your project needs and building the right team can make the difference between project success or failure. Dedicating more time at the beginning of a project to detail the specific skillsets you require is a critical first step. During the next step, building and hiring the team, it’s important to not take shortcuts and bring on board professionals who possess the level of expertise you need. Hiring in-house resources may be a good option, however it may not be feasible or scalable for every function your projects require. Outsourcing these roles to a strategic partner who specializes in areas such as system validation, compliance, quality and data integrity may be a good option for enhanced expertise, value, scale, and ROI.</p>The post <a href="https://www.pharmaadvancement.com/market-moves/building-the-right-team-and-resource-model-to-support-quality-system-and-validation-activities/">Building the Right Team and Resource Model to Support Quality System and Validation Activities</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing</title>
		<link>https://www.pharmaadvancement.com/pharma-news/thermo-fisher-new-hmw-kit-powers-long-read-dna-sequencing/</link>
		
		<dc:creator><![CDATA[API PA]]></dc:creator>
		<pubDate>Fri, 08 Aug 2025 12:23:31 +0000</pubDate>
				<category><![CDATA[Manufacturing]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Customised Solutions]]></category>
		<guid isPermaLink="false">https://www.pharmaadvancement.com/uncategorised/thermo-fisher-new-hmw-kit-powers-long-read-dna-sequencing/</guid>

					<description><![CDATA[<p>Thermo Fisher Scientific has unveiled the Applied Biosystems MagMAX HMW DNA Kit, a new solution that supports both manual and automated workflows to enable extraction of High Molecular Weight (HMW) DNA, tailored for use in long-read DNA sequencing. Developed for efficiency and consistency, the kit makes it easier to isolate large, intact, high-integrity DNA fragments [&#8230;]</p>
The post <a href="https://www.pharmaadvancement.com/pharma-news/thermo-fisher-new-hmw-kit-powers-long-read-dna-sequencing/">Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></description>
										<content:encoded><![CDATA[<p><span style="font-weight: 400;">Thermo Fisher Scientific has unveiled the Applied Biosystems MagMAX HMW DNA Kit, a new solution that supports both manual and automated workflows to enable extraction of High Molecular Weight (HMW) DNA, tailored for use in long-read DNA sequencing.</span></p>
<p><span style="font-weight: 400;">Developed for efficiency and consistency, the kit makes it easier to isolate large, intact, high-integrity DNA fragments from a wide range of sample types. With this, the laboratories can achieve dependable results while keeping processing time to a minimum.</span></p>
<p><span style="font-weight: 400;">As genomic applications continue to grow in sectors like biotech, pharmaceuticals, clinical research, and academic fields, the need for more efficient methods suited to long-read DNA sequencing has become evident. Until recently, scientists often had to rely on separate extraction kits depending on their sample type and process, which led to inconsistent results and delayed timelines due to the demands of manual preparation.</span></p>
<p><span style="font-weight: 400;">The MagMAX HMW DNA Kit responds to this challenge by offering a consistent method for obtaining high-quality HMW DNA. It produces fragments larger than 100 kilobases in under two hours and typically requires only 20 to 30 minutes of hands-on time. Being compatible with Thermo Scientific KingFisher Duo Prime, Flex, and Apex platforms, it allows labs to scale workflow easily while maintaining reproducibility. Its flexible design also includes a range of protocols, enabling labs to scale their operations as project demands shift.</span></p>
<p><span style="font-weight: 400;">“Researchers working with long-read sequencing face diverse sample types and throughput requirements but share the need for reliable, efficient DNA isolation. Our MagMAX HMW DNA Kit provides a streamlined, automated option that reduces bottlenecks and enables researchers to focus more on discovery,” said Kevin Lowitz, vice president and general manager, sample preparation at Thermo Fisher. </span></p>
<p><span style="font-weight: 400;">“Our lab relies on long-read sequencing to study genomic structures and variations linked to human disease. The MagMAX HMW DNA Kit offers a simple, scalable solution that consistently produces high molecular weight DNA, ensuring we have trustworthy data for our research.,” said Alexis Tapanes-Castillo, PhD, associate professor of Biology, Lab Director, St. Thomas University.</span></p>
<p><span style="font-weight: 400;">Designed for speed and precision, the MagMAX HMW DNA Kit provides researchers with high-integrity DNA in less time, helping drive faster breakthroughs in oncology and genomics</span></p>The post <a href="https://www.pharmaadvancement.com/pharma-news/thermo-fisher-new-hmw-kit-powers-long-read-dna-sequencing/">Thermo Fisher New HMW Kit Powers Long-Read DNA Sequencing</a> appeared first on <a href="https://www.pharmaadvancement.com">Pharma Advancement</a>.]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
